Rejholec V
Z Rechtsmed. 1975 May-Jun;34(5-6):141-8.
124 patients afflicted with rheumatoid arthritis were being treated with gold salts or antimalarial preparations with the addition of corticoids as well as other antirheumatic preparations. If the Lansbury-Index fell under 30% of the initial value, the therapy was interrupted, and that in 84 patients. One half of these patients were then given Perclusone (Clofezone) in the dose of 600 mg daily for 4 years. The other half of patients -- as control group-- were given various non-steroid antirheumatics, mostly acetylsalicylic acid, phenylbutazon or indomethacin in normal doses. The course of the disease of both groups was followed up clinically and the Lansbury-Index as well as the number and duration of reactivations were determined. In the group treated with Perclusone, the previously obtained remissions remained substantially more stable, only rarely reactivations ensued and their duration was then also remarkably shorter. Tolerance of Perclusone was very good, no side-effects whatsoever have been ascertained. In the group treated with other antirheumatics distinctly more frequent and longer-lasting reactivations were ascertained. Tolerance of these drugs was generally worse and they had to be changed more frequently. Perclusone has thus proved efficient as a very good stabilizing drug in patients suffering from rheumatoid arthritis.
124名类风湿性关节炎患者正在接受金盐或抗疟制剂治疗，并加用皮质类固醇以及其他抗风湿制剂。如果兰斯伯里指数降至初始值的30%以下，则中断治疗，84名患者出现这种情况。然后，这些患者中的一半每天服用600毫克佩尔克洛松（氯苯唑酮），持续4年。另一半患者作为对照组，服用各种非甾体类抗风湿药，大多为正常剂量的乙酰水杨酸、保泰松或吲哚美辛。对两组患者的病情进行了临床随访，并测定了兰斯伯里指数以及复发的次数和持续时间。在用佩尔克洛松治疗的组中，先前获得的缓解明显更稳定，很少复发，而且复发持续时间也明显更短。佩尔克洛松的耐受性非常好，未发现任何副作用。在用其他抗风湿药治疗的组中，复发明显更频繁且持续时间更长。这些药物的耐受性通常较差，不得不更频繁地更换药物。因此，佩尔克洛松已被证明是治疗类风湿性关节炎患者的一种非常有效的稳定药物。
